申请人:Bayer Pharma Aktiengesellschaft
公开号:US20170253602A1
公开(公告)日:2017-09-07
The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
本申请涉及新型(3-羟基苯基)氨基取代的吡啶并[2,3-b][1,5]苯二氮杂二环己酮衍生物,以及其制备方法,单独或联合用于治疗和/或预防疾病的用途,以及用于生产用于治疗和/或预防疾病的药物的用途,特别是对血管生成障碍和细胞过度增殖障碍的治疗,其中新生血管化起作用,例如眼科疾病和癌症和肿瘤。这种治疗可以作为单独治疗或与其他药物或进一步治疗措施结合使用。